The 2024 Watch List aims to identify and describe technologies and issues related to the care of children and youth with medical complexity that are likely to affect health care delivery and planning in Canada in the next 5 years. By doing so, the 2024 Watch List will help health care decision-makers anticipate future challenges and opportunities for improving the delivery of care for children and youth with medical complexity.
Target Zero is a new initiative that aims to improve the time to access for patients in Canada for new drugs that are proven to be effective.
The ambitious goal of Target Zero is to achieve zero days between Health Canada’s regulatory approval of a drug and CADTH’s reimbursement recommendation to participating public drug plans.
CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in health technology assessments (HTAs).
We are testing a new approach that brings the societal perspective to our economic evaluations of certain new drugs.
Current Consultation Status: Open
Consultation Period: March 28, 2024, to April 26, 2024
CADTH is updating the procedures for provisional funding algorithms as part of our commitment to examine new ways of working and our ongoing efforts to improve the drug reimbursement pathway.
Qualified rare disease registry owners can submit funding proposals to enhance the infrastructure, data quality, and utility of rare disease registries.
CADTH is launching an open call for funding to support efforts to improve the quality and usability of real-world data from rare disease registries.